Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald L Denardo

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 7, 2005
Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetrySui Shen, Sally J DeNardo, Carol M Richman, et al.
Cancer Biotherapy & Radiopharmaceuticals|May 6, 2008
Short communication: nanoparticle thermotherapy and external beam radiation therapy for human prostate cancer cellsJoerg Lehmann, Arutselvan Natarajan, Gerald L Denardo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2004
Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparisonBarry W Wessels, Wesley E Bolch, Lionel G Bouchet, et al.
Blood|January 4, 2003
Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenograftsJoseph M Tuscano, Robert T O'Donnell, Laird A Miers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancerSally J DeNardo, Carol M Richman, Huguette Albrecht, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 7, 2007
Recombinant expression of the beta-subunit of HLA-DR10 for the selection of novel lymphoma targeting moleculesHuguette Albrecht, Monique Cosman, Maria Ngu-Schwemlein, et al.
International Journal of Oncology|June 15, 2006
Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting moleculesPatricia A Burke, Jeffrey P Gregg, Brandon Bakhtiar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing miceSally J DeNardo, Zhengsheng Yao, Kit S Lam, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 17, 2007
Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphomaGerald L DeNardo, Arutselvan Natarajan, Saphon Hok, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Selection and characterization of anti-MUC-1 scFvs intended for targeted therapyMichelle D Winthrop, Sally J DeNardo, Huguette Albrecht, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 7, 2005
Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetrySui Shen, Sally J DeNardo, Carol M Richman, et al.
Cancer Biotherapy & Radiopharmaceuticals|May 6, 2008
Short communication: nanoparticle thermotherapy and external beam radiation therapy for human prostate cancer cellsJoerg Lehmann, Arutselvan Natarajan, Gerald L Denardo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2004
Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparisonBarry W Wessels, Wesley E Bolch, Lionel G Bouchet, et al.
Blood|January 4, 2003
Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenograftsJoseph M Tuscano, Robert T O'Donnell, Laird A Miers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancerSally J DeNardo, Carol M Richman, Huguette Albrecht, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 7, 2007
Recombinant expression of the beta-subunit of HLA-DR10 for the selection of novel lymphoma targeting moleculesHuguette Albrecht, Monique Cosman, Maria Ngu-Schwemlein, et al.
International Journal of Oncology|June 15, 2006
Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting moleculesPatricia A Burke, Jeffrey P Gregg, Brandon Bakhtiar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing miceSally J DeNardo, Zhengsheng Yao, Kit S Lam, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 17, 2007
Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphomaGerald L DeNardo, Arutselvan Natarajan, Saphon Hok, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Selection and characterization of anti-MUC-1 scFvs intended for targeted therapyMichelle D Winthrop, Sally J DeNardo, Huguette Albrecht, et al.
Pageof 7